This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Silverstein, R. L. Articles by Nachman, R. L. Search for Related Content PubMed PubMed Citation Articles by Silverstein, R. L. Articles by Nachman, R. L. Related Collections Angiogenesis Chronic ischemic heart disease

(Circulation. 1999;100:783-785.)
© 1999 American Heart Association, Inc.

Editorials

Angiogenesis and Atherosclerosis

The Mandate Broadens

Roy L. Silverstein, MD; Ralph L. Nachman, MD

From Weill Medical College of Cornell University, Department of Medicine, Division of Hematology/Medical Oncology, New York, NY.

Correspondence to Roy L. Silverstein, MD, Weill Medical College of Cornell University, Department of Medicine, Division of Hematology/Medical Oncology, 1300 York Ave, Room C606, New York, NY 10021. E-mail rlsilve@mail.med.cornell.edu

Key Words: Editorials • angiogenesis • atherosclerosis • restenosis • cell adhesion molecules

	Introduction

 
Among the most exciting developments in vascular medicine is the targeting of specific molecular regulators of blood vessel growth and development for therapeutic benefit. Angiogenesis, whether physiological, such as occurs during embryogenesis, or pathological, such as occurs during wound healing and tumor progression, requires a highly coordinated series of events that includes endothelial cell proliferation, migration, tube and lumen formation, and in some cases, recruitment of smooth muscle and other adventitial cells. A large number of studies in cellular systems and animal models have led to identification and characterization of specific factors that can either stimulate or inhibit angiogenesis.¹ These studies were mainly stimulated by Folkman's hypothesis that tumor growth beyond a few millimeters requires recruitment and formation of a new microcirculation, and thus, that blood vessel–directed therapy might be effective in treating cancer. Translational research has now been initiated by several groups to test the hypothesis that local delivery of angiogenic agents, such as vascular endothelial growth factor (VEGF) or basic fibroblast growth factor (bFGF), by various strategies, including viral vectors, naked DNA, or purified recombinant proteins, may improve blood flow to ischemic tissues in patients with advanced atherosclerosis. In some cases, preliminary data have been reported and appear promising.²

Specific antiangiogenic therapies are also now in the clinical-trial stage for a broadening group of common diseases, including cancer, macular degeneration, and rheumatoid arthritis. Recent studies in rodent models suggest that antiangiogenic agents may limit adipose mass in hereditary obesity and may slow progression of atheroma.³ The latter result, . . . [Full Text of this Article]

This article has been cited by other articles:

				R. Moura, M. Tjwa, P. Vandervoort, S. Van kerckhoven, P. Holvoet, and M. F. Hoylaerts Thrombospondin-1 Deficiency Accelerates Atherosclerotic Plaque Maturation in ApoE-/- Mice Circ. Res., November 7, 2008; 103(10): 1181 - 1189. [Abstract] [Full Text] [PDF]

				R Tabibiazar and S.G Rockson Angiogenesis and the ischaemic heart Eur. Heart J., June 1, 2001; 22(11): 903 - 918. [PDF]

				X.-M. Zhao, Y. Hu, G. G. Miller, R. N. Mitchell, and P. Libby Association of Thrombospondin-1 and Cardiac Allograft Vasculopathy in Human Cardiac Allografts Circulation, January 30, 2001; 103(4): 525 - 531. [Abstract] [Full Text] [PDF]

				K. Hida, J. Wada, H. Zhang, K. Hiragushi, Y. Tsuchiyama, K. Shikata, and H. Makino Identification of genes specifically expressed in the accumulated visceral adipose tissue of OLETF rats J. Lipid Res., October 1, 2000; 41(10): 1615 - 1622. [Abstract] [Full Text]